Clinical Trial: Study of BPI-572070 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07435038) titled 'Study of BPI-572070 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS' on Jan. 19.

Brief Summary: Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.

Study Start Date: Feb. 12

Study Type: INTERVENTIONAL

Condition: Non-small Cell Lung Cancer (NSCLC) Colorectal Cancer (CRC) Pancreatic Ductal Adenocarcinoma (PDAC) Advanced Solid Tumors

Intervention: DRUG: BPI-572270

Oral Tablets

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Betta Pharmaceuticals Co., Ltd.

Published by HT Digital Content Services with permission from Health Daily Digest...